Lucio N. Gordan, MD Discusses Findings of Phase 3 Clinical Trial Supporting Advanced Treatments for Multiple Myeloma in National Broadcast

Fort Myers, Fla., April 25, 2024 – Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio Gordan, MD will join a panel of industry experts for a discussion of key clinical data and insights in treatment options for newly-diagnosed, transplant ineligible patients diagnosed with multiple myeloma. The live, national broadcast will explore the findings of a Phase 3 MAIA trial conducted with participation from FCS, comparing DRd and Rd, alongside an Indirect Treatment Comparison and the TAURUS Real-World Evidence study, both evaluating DRd vs VRd. FCS medical oncologist and hematologist Joseph R. Mace, MD co-authored the study.

Image Credit: © Florida Cancer Specialists & Research Institute, LLC

Dr. Gordan said, “Clinical trials are integral to ongoing innovations and advancements in cancer treatment. Increasingly, our precision oncology insights and real-world evidence platform are enhancing our studies and informing clinical decisions.”

MAIA is an ongoing phase 3 trial that enrolled patients, beginning in 2015 through 2017 at 176 hospitals in 14 countries across North America, Europe, the Middle East, and the Asia-Pacific region. Eligible patients were age 18 or older, newly diagnosed with multiple myeloma, and ineligible for high-dose chemotherapy with autologous stem-cell transplantation because of their age or comorbidities. Results of the study support the frontline use of daratumumab plus lenalidomide and dexamethasone (Darzalex®) for patients with multiple myeloma who are ineligible for transplantation, as it increased overall survival and progression-free survival. The second most common hematologic malignancy in the U.S., multiple myeloma is a rare, incurable blood cancer that affects plasma cells found in bone marrow.

Details on registration and attending the event are available here: https://form.jotform.com/240454918384059.Fort Myers, Fla., April 25, 2024 – Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio Gordan, MD will join a panel of industry experts for a discussion of key clinical data and insights in treatment options for newly-diagnosed, transplant ineligible patients diagnosed with multiple myeloma. The live, national broadcast will explore the findings of a Phase 3 MAIA trial conducted with participation from FCS, comparing DRd and Rd, alongside an Indirect Treatment Comparison and the TAURUS Real-World Evidence study, both evaluating DRd vs VRd. FCS medical oncologist and hematologist Joseph R. Mace, MD co-authored the study.

Dr. Gordan said, “Clinical trials are integral to ongoing innovations and advancements in cancer treatment. Increasingly, our precision oncology insights and real-world evidence platform are enhancing our studies and informing clinical decisions.”

MAIA is an ongoing phase 3 trial that enrolled patients, beginning in 2015 through 2017 at 176 hospitals in 14 countries across North America, Europe, the Middle East, and the Asia-Pacific region. Eligible patients were age 18 or older, newly diagnosed with multiple myeloma, and ineligible for high-dose chemotherapy with autologous stem-cell transplantation because of their age or comorbidities. Results of the study support the frontline use of daratumumab plus lenalidomide and dexamethasone (Darzalex®) for patients with multiple myeloma who are ineligible for transplantation, as it increased overall survival and progression-free survival. The second most common hematologic malignancy in the U.S., multiple myeloma is a rare, incurable blood cancer that affects plasma cells found in bone marrow.

Details on registration and attending the event are available here: https://form.jotform.com/240454918384059.